San Francisco 29 April 2019 The Report Nanomedicine Market Analysis By Products, (Therapeutics, Regenerative Medicine,
Diagnostics), By Application, (Clinical Oncology, Infectious diseases), By
Nanomolecule (Gold, Silver, Iron Oxide, Alumina), & Segment Forecasts, 2018
- 2025
The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025,
according to a new report by Grand View Research, Inc. Development of novel
nanotechnology-based drugs and therapies is driven by the need to develop
therapies that have fewer side effects and that are more cost-effective than
traditional therapies, in particular for cancer.
Application of nanotechnology-based
contrast reagents for diagnosis and monitoring of the effects of drugs on an
unprecedented short timescale is also attributive drive growth in the coming
years. Additionally, demand for biodegradable implants with longer lifetimes
that enable tissue restoration is anticipated to influence demand.
As per the WHO factsheet, cancer is found
to be one of the major causes of mortality and morbidity worldwide, with
approximately 14 million new cases in 2012 and 8.2 million cancer-related
deaths. Thus, demand for nanomedicine in order to curb such high incidence rate
is expected to boost market progress during the forecast period.
Solutions such as nanoformulations with
triggered release for tailor-made pharmacokinetics, nanoparticles for local
control of tumor in combination with radiotherapy, and functionalized
nanoparticles for targeted in-vivo activation of stem cell production are
anticipated to drive R&D, consequently resulting in revenue generation in
the coming years.
Biopharmaceutical and medical devices
companies are actively engaged in development of novel products as demonstrated
by the increasingly growing partnerships between leading enterprises and
nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk
signed a global collaboration and a licensing agreement for development and
discovery of innovative drugs with multi-specific nanobodies. This strategic
partnership is anticipated to rise the net annual sales of the products
uplifting the market growth.
However, in contrary with the applications
of nanotechnology, the entire process of lab to market approval is a tedious
and expensive one with stringent regulatory evaluation involved thereby leading
investors to remain hesitant for investments.
Access Research Report of Nanomedicine Market @ http://www.grandviewresearch.com/industry-analysis/nanomedicine-market
Further key findings from the report suggest:
· Therapeutics accounted for the largest
share of market revenue in 2016 owing to presence of nanoemulsions,
nanoformulations, or nanodevices
· These devices possess the ability to cross
biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and
Emend is attributive for higher revenue generation
· Presence of substantial number of products
manufactured through the use of microbial sources can be attributed for the
largest share
· In-vitro diagnostics
is expected to witness lucrative progress as a result of R&D carried out in
this segment
· Introduction of nano-enabled biomarkers,
vectors and contrast agents with high-specificity and sensitivity are
attributive for projected progress
· Clinical cardiology is expected to witness
the fastest growth through to 2025 owing to development in
nano-functionalization and modification of surfaces for increased
biocompatibility of implants in treatment of late thrombosis
· Moreover, an abundance of research
publications and patent filings from European region with a share of about 25%
in nanomedicine-related publications is supportive for revenue generation from
European economies
·
Asia Pacific is estimated to witness the
fastest growth over the forecast period
· Factors responsible include government and
regulatory authorities that have implemented a framework to encourage R&D
collaborations and framework extension.
· Key players operating in this industry
include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc.,
Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and
Merck
· Active expansion strategies are undertaken
by a number of the major market entities in order to strengthen their position
· North America dominated the industry in
2016, accounting for a 42% of total revenue
· Presence of key participants operating in
the region are involved in collaborative activities are attributive for the
largest share of North America in sector revenue
Browse more reports of this category by Grand View
Research at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the nanomedicine market on the basis of product, application,
nanomolecule type, and region:
Nanomedicine Product Outlook (Revenue, USD
Billion; 2013 - 2025)
·
Therapeutics
·
Regenerative medicine
·
In-vitro diagnostics
·
In-vivo diagnostics
·
Vaccines
Nanomedicine Application Outlook (Revenue,
USD Billion; 2013 - 2025)
·
Clinical Oncology
·
Infectious diseases
·
Clinical Cardiology
·
Orthopedics
·
Others
Nanomedicine Nanomolecule Type Outlook
(Revenue, USD Billion; 2013 - 2025)
·
Nanoparticles
·
Nanoshells
·
Nanotubes
·
Nanodevices
Nanomedicine Regional Outlook (Revenue, USD
Billion; 2013 - 2025)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa (MEA)
Access Press Release of
Nanomedicine Market@ https://www.grandviewresearch.com/press-release/global-nanomedicine-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
